In an ocular surface disease mouse model, it was demonstrated that an LFA-1 antagonist (Lifitegrast) downregulated clinical dry eye severity via preferentially blocking Th1 cell migration [34]. This evidence concerns the gene ITGAL and dry eye syndrome.